TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a potent inducer of apoptosis in tumor cells and holds a promise as a therapeutic agent against cancer. To elucidate the death signaling evoked by TRAIL, we performed a functional genetic screening and rescued TRAIL-resistant Jurkat clones harboring ribosomal protein S6 (rpS6) cDNA in anti-sense frame. Reduction of rpS6 expression in Jurkat and HeLa cells attenuated apoptosis induced by TRAIL, but not those by other cell death signals, including tumor necrosis factor-a and cycloheximide, etoposide, doxorubicin, tunicamycin and staurosporine. Death receptor (DR) 4, but not DR5, was downregulated in rpS6 knockdown cells. Conversely, the sensitivity to TRAIL was increased by the ectopic expression of wild-type rpS6 and further by phosphodefective rpS6 mutant (S6-SS235,6AA), but not by phospho-mimic rpS6 mutant (S6-SS235,6DD). Also, unphosphorylatable rpS6 knock-in mouse embryo fibroblasts (rpS6 PÀ/À MEFs) were more sensitive to TRAIL than control MEFs. In addition, SKHep-1 tumor cells, which express less phospho-rpS6 and are more sensitive to TRAIL than other tumor cells, became effectively desensitized to TRAIL after rpS6 knockdown. These results suggest that rpS6, especially in its unphosphorylated form, is a selective mediator of TRAIL-induced apoptosis.
Introduction
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is an apoptosis-inducing ligand and is a member of the tumor necrosis factor superfamily (Wiley et al., 1995; Pitti et al., 1996) . TRAIL is unique among the cytokines in that it suppresses tumor and efficiently induces tumor cell death by binding to its receptors, TRAIL-R1 (death receptor (DR) 4) and TRAIL-R2 (DR5) (Wu et al., 1997; Pan et al., 1997a, b) . Thus, TRAIL could potentially serve as a useful chemotherapeutic agent and is currently developed for clinical trials using corresponding agonistic antibody and recombinant TRAIL (Ashkenazi et al., 1999; Nebbioso et al., 2005; reviewd in Fesik, 2005) . Also, combinatory approaches utilizing TRAIL with several antitumor drugs are under development for chemotherapeutics. While decoy receptor, TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) lacking cytoplasmic death domain, FLIP and caspase-8 were reported to play critical roles in the regulation of TRAIL-mediated apoptosis (Sheridan et al., 1997; Pan et al., 1997a; Kim et al., 2000) , the sequence of TRAIL-selective events occurring downstream of the receptors is not fully understood.
The mTOR-S6K1 (mammalian target of rapamycin-S6 kinase 1) pathway was attracted as a key regulator of cell and body size in response to a wide range of external stimuli (reviewed in Inoki et al., 2005) . In addition, S6K1 exhibits anti-apoptotic activity against intrinsic or extrinsic apoptotic stimuli, including TRAIL (Stromberg et al., 2004; Beuvink et al., 2005; Panner et al., 2005) . While ribosomal protein S6 (rpS6) is one of the downstream effectors of the mTOR-S6K1 pathway, the role of rpS6 in cell death has not been addressed yet. rpS6 is phosphorylated at the C-terminal region in response to various external signals (Krieg et al., 1988; Franco and Rosenfeld, 1990; Pende et al., 2004) . The phosphorylation of rpS6 was believed to be necessary for the translational regulation of several mRNAs (Jefferies et al., 1997) . However, recent report using knock-in mice suggested that the unphosphorylatable rpS6 functions in protein translation at least as good as the wild type (Ruvinsky et al., 2005) . Especially, the association of rpS6 modification with cell death is not known.
In the present study, we isolated rpS6 cDNA in antisense frame from retroviral human cDNA libraries during death-rescue modifier screening. We found that the downregulation of rpS6 expression desensitized tumor cells to apoptosis induced by TRAIL, but not by other signals, including etoposide. This pro-apoptotic activity of rpS6 is mainly mediated by its unphosphorylatable form, postulating rpS6 as a mediator of TRAIL-induced apoptosis.
Results
Reduced expression of rpS6 selectively suppresses tumor cell death induced by TRAIL As described previously (Kim et al., 2003) , we have screened human cDNA libraries by reverse genetic approaches to isolate genes regulating TRAIL-induced apoptosis. Jurkat 32H cells equipped with tetracycline off-inducible expression system were infected with retroviral cDNA libraries and then treated with 25 ng/ ml TRAIL. In most cases, 30-40% of transduction was achieved as determined by doping of the library with retroviral marker, pTRA-green fluorescent protein (GFP). TRAIL-resistant clones were selected out of total 10 9 cells after 48 h of TRAIL treatment and isolated by fluorescence-activated cell sorting (FACS) analysis. DNA sequencing analysis revealed that two of the clones expressed Bcl-X L , eight clones expressed FLICE-inhibitory protein (FLIP) and one clone harbored rpS6 cDNA in anti-sense frame. FACS analysis showed that TRAIL treatment increased propidium iodide uptake in Jurkat 32H cells (Figure 1a, upper panel) . However, the expression of rpS6 anti-sense cDNA (AS-S6) in the inducible expression plasmid significantly protected Jurkat 32H-AS-S6 cells from apoptosis, showing comparable propidium iodide uptake to the untreated control, while the treatment with doxycycline-sensitized Jurkat 32H-AS-S6 cells to TRAIL (Figure 1a , middle panel). Similar protective effects were observed in Jurkat 32H-FLIP cells Figure 1 Isolation of Jurkat 32H cells harboring anti-sense cDNA of ribosomal protein S6 (rpS6) and showing resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death. (a) Fluorescence-activated cell sorting (FACS) analysis of Jurkat clones. Jurkat 32H (6C3) and Jurkat (2-51) cells harboring rpS6 anti-sense (AS-S6) and c-FLIP cDNA, respectively, were preincubated with doxycycline (Dox, 50 ng/ml) for 48 h and then left untreated (control) or exposed to TRAIL (25 ng/ml) for 8 h. Cells were then incubated with 50 mg/ml propidium iodide (PI) and analysed with FACScalibur. (b) Doxycycline-dependent expression levels of rpS6 mRNA and protein. Jurkat 32H (6C3) cells were left untreated or incubated with doxycycline for 48 h. Cell extracts were prepared and analysed with western blotting using anti-rpS6 and anti-a-tubulin antibodies (upper two panels). Total RNA was extracted and analysed for rpS6 (anti-sense cDNA) and b-actin by reverse transcription (RT)-PCR (lower two panels). We also analysed the ability of rpS6 knockdown to confer resistance to TRAIL in HeLa cells. The expression of rpS6 was downregulated by rpS6 anti-sense cDNA or short hairpin RNA (shRNA) (Figures 1c and  d Figure 1 ; data not shown). These observations suggest that rpS6 mediates TRAILinduced apoptosis of tumor cells.
We then assessed the sensitivity of Jurkat 32H-AS-S6 cells to apoptosis triggered by different signals (Figure 2a) . In contrast to TRAIL, the modulation of rpS6 expression with doxycycline did not affect cells' sensitivity to apoptosis triggered by tumor necrosis factor-a, staurosporine or etoposide. Similarly, HeLa cells stably expressing rpS6 anti-sense cDNA (no. 1) or shRNA (no. B1) were resistant to TRAIL, but not to doxorubicin or tunicamycin (Figure 2b) , showing significant and selective resistance to TRAIL. Other HeLa stable clones showing the reduced expression of rpS6 also exhibited similar resistance to TRAIL (data not shown). These results indicate that rpS6 may selectively mediate TRAIL-induced apoptosis.
Ectopic expression of rpS6 increases TRAIL-induced apoptosis Conversely, we tested whether the increased expression of rpS6 affects TRAIL-induced apoptosis. HeLa cells overexpressing rpS6, which were viable and showed no significant difference in cell viability, were more sensitive to TRAIL than control cells (Figure 3a) . The expression of GFP-S6 was confirmed with western blot analysis (Supplementary data Figure 2 ). When exposed to
Figure 2 Downregulation of ribosomal protein S6 (rpS6) expression induces selective resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). (a) Jurkat 32H-AS-S6 cells were incubated with TRAIL (25 ng/ml) for 12 h, tumor necrosis factor (TNF)-a (30 ng/ml) with cycloheximide (CHX, 5 mg/ml) for 12 h, Fas ligand (FasL 200 ng/ml) for 12 h, etoposide (50 mg/ml) for 48 h or staurosporine (0.5 mM) for 24 h after preincubation with doxycycline (Dox) or dimethyl sulfoxide (DMSO) for 48 h. (b) HeLa cells stably expressing green fluorescent protein (GFP)-AS-S6 cDNA (no. 1) or short hairpin RNA (shRNA)-S6 (no. B1) were exposed to TRAIL (50 ng/ml) for 3 h, TNF-a (30 ng/ml) with CHX (5 mg/ml) for 3 h, tunicamycin (12 mg/ml) for 24 h or doxorubicin (125 ng/ml) for 24 h. Cells were stained with ethidium homodimer-1 and observed under a fluorescence microscope. Bars depict mean±s.d. (n ¼ 3). P-values were obtained using analysis of variance (ANOVA) and Bonferroni tests. (rpS6) potentiates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. (a) HeLa cells were transfected with green fluorescent protein (GFP) (control) or GFP-S6 for 24 h and then left untreated (control) or exposed to TRAIL (25 ng/ml) for 3 h, tumor necrosis factor (TNF)-a (30 ng/ml) with cycloheximide (CHX) (5 mg/ml) for 3 h, tunicamycin (12 mg/ml) for 24 h, staurosporine (0.5 mM) for 24 h or doxorubicin (125 ng/ml) for 24 h. (b) HeLa cells were transfected with GFP and either control (pcDNA) or one of ribosomal protein expression vectors (S6, S2, S3 and S20). After 24 h, cells were left untreated or exposed to 50 ng/ml TRAIL for 3 h. Cell death ratio was evaluated by examining the morphology of GFP-positive cells and by counting the fragmented nuclei after staining with Hoechst 33258. Bars indicate mean ± s.d.
TRAIL, death rate increased from 37 to 52% at 3 h after TRAIL treatment. However, the overexpression of rpS6 did not enhance cell death triggered by other death signals, including etoposide, tunicamycin, staurosporine and doxorubicin. These results suggest that the increased expression of rpS6 also potentiates TRAILselective apoptosis. We further assessed the effects of other ribosomal proteins on TRAIL-induced cell death. Unlike rpS6, the ectopic expression of rpS2, rpS3 or rpS20 did not potentiate TRAIL-induced cell death (Figure 3b) , indicating that the contribution of rpS6 to TRAIL-induced apoptosis may be specific among those ribosomal proteins we tested.
Downregulation of phosphorylated rpS6 and DR4 in rpS6 knockdown cells Given the proposed role of S6K1 exhibiting antiapoptotic activity against TRAIL (Panner et al., 2005) , we addressed the contribution of S6K1 to TRAIL signaling. Consistently, we found that ectopic expression of wild-type S6K1 or its constitutive active form (S6K1 T389E) induced the phosphorylation of rpS6 in HeLa cells, as examined with western blot analysis using phospho (p235,236)-rpS6-specific antibody (Supplementary data Figure 3a , upper panel). In the same cells, TRAIL-induced apoptosis was suppressed in a serumfree condition (75-55% at 4 h after TRAIL treatment) (Supplementary data Figure 3a , lower panel). Also, rapamycin, an mTOR inhibitor, inhibited the phosphorylation of rpS6 and sensitized HeLa cells to TRAIL (47-62%) (Supplementary data Figure 3b ). These observations raise a possibility that the phosphorylated rpS6 may function to suppress TRAIL-induced apoptosis.
However, the examination of rpS6 phosphorylation at Ser 235 and 236 with western blotting showed that compared to wild-type cells, the amounts of phosphorpS6 as well as rpS6 were markedly reduced in Jurkat 32H-AS-S6 (Figure 4a ) and HeLa-AS-S6 cells (Figure 4b ). We found that caspases-8 and -3 were less activated in TRAIL-resistant Jurkat 32H-AS-S6 and HeLa-AS-S6 cells than their control cells during TRAIL-induced apoptosis, while the expression of other related proteins, including AKT, was not affected (Figure 4 ; data not shown). These observations that Jurkat 32H-AS-S6 and HeLa-AS-S6 cells were resistant to TRAIL in spite of the reduced phosphorylation levels of rpS6 suggest that cells' resistance to TRAIL may not result from the increased phosphorylation of rpS6 at the C-terminal region, including Ser 235 and 236, though S6K1 suppresses TRAIL-induced apoptosis.
We further examined how the reduced expression of rpS6 exhibits selective resistance to TRAIL. Because we observed less activation of caspase-8 in rpS6 knockdown cells than their wild-type cells during TRAIL-induced apoptosis, we extensively analysed the expression levels of various proteins functioning upstream of caspase-8 and compared those between wild-type and rpS6 knockdown cells. Interestingly, western blotting elucidated that DR4, but not DR5, was dramatically downregulated in HeLa and SKHep-1 rpS6 knockdown cells (Figures 4c and d ). There were no differences in the amounts of other proteins, including FADD, caspase-8, Bcl-2, S6K1, phospho-Thr35/47-4EBP-1 and phosphoThr389-S6K1. RT-PCR analysis showed that DR4 mRNA level was also reduced in SKHep-1 rpS6 knockdown cells (Supplementary data Figure 4 ). In addition, downregulation of DR4 expression by shRNA partially but significantly suppressed TRAIL-induced apoptosis in HeLa and SKHep-1 cells (data not shown), indicating that DR4 contributes to TRAIL-induced apoptosis in these cells. Further, reconstitution of DR4 could revert TRAIL-resistance in HeLa or SKHep-1 rpS6 knockdown cells (Figures 4e and f) . These results suggest that the downregulation of rpS6 in tumor cells may exhibit selective resistance to TRAIL via the expressional regulation of DR4.
Sensitizing effects of unphosphorylatable rpS6 on TRAIL-induced cell death To further characterize the role of rpS6 in TRAIL signaling, we addressed the relevance of rpS6 phosphorylation at C-terminal region to its pro-apoptotic activity. Three phospho-defective rpS6 mutants (S6-S235A, S6-S236A, S6-SS235,6AA) and a phosphomimic rpS6 mutant (S6-SS235,6DD), where 235 and 236 serine residues were replaced with alanine or apartate, were generated as GFP-fusion protein to distinguish those from endogenous rpS6 (Figure 5a ). Western blotting confirmed that the phospho-defective rpS6 mutants were not phosphorylated in the transfected HeLa cells (Figure 5c ). Ectopic expression of wild-type or phospho-defective mutant of rpS6 sensitized HeLa cells to TRAIL. On the contrary, the phospho-mimic rpS6 mutant failed to affect TRAILinduced apoptosis (Figure 5b) . Similarly, the phosphomimic rpS6 mutant did not show any protective effects against TRAIL in other tumor cells, including Chang's liver and SKHep-1 cells (data not shown).
Also, the phospho-defective rpS6 mutants were more effective to increase TRAIL-induced apoptosis (33-60%) than wild-type rpS6 (Figure 5d ). Because GFP-S6 was phosphorylated in the transfected HeLa cells (Figure 5c ), we then eliminated the contribution of S6K1 and the phosphorylated form of rpS6 to apoptosis by using rapamycin. Compared to control, ectopic expression of rpS6 increased TRAIL-induced apoptosis from 44 to 64% in the presence of rapamycin (Figure 5d) . Then, the incubation of cells expressing rpS6 with rapamycin also increased TRAIL-induced apoptosis from 51 to 64%, which is almost comparable to those of HeLa cells expressing phosphodefective rpS6 mutants. However, rapamycin did not increase TRAIL-induced apoptosis of cells expressing phospho-defective rpS6 mutant. The inhibitory effects of rapamycin on rpS6 phosphorylation were confirmed by western blotting (Figure 5d, insert) . These results suggest that the unphosphorylated rpS6, but not the phospho-rpS6, potentiates TRAIL-induced apoptosis.
The pro-apoptotic activity of unphosphorylated rpS6 was further examined in unphosphorylatable rpS6 knock-in mouse embryo fibroblasts (rpS6 PÀ/À MEFs). The rpS6 PÀ/À MEFs express comparable amount of phospho-defective rpS6 mutant (S235,236,240,244,247A) to wild-type rpS6 (Figure 6a ). Because MEFs are resistant to TRAIL-induced apoptosis, wild-type and rpS6 PÀ/À MEFs were exposed to TRAIL after ectopic expression with DR4. Determination of cell viability showed that rpS6 PÀ/À MEFs were more sensitive to TRAIL than wild-type cells, but were as sensitive as wildtype cells to etoposide (Figure 6b ). These results further support that the unphosphorylated rpS6 functions as a pro-apoptotic molecule in TRAIL signaling pathway. Reduction of phospho-rpS6 in rpS6 knockdown cells. Jurkat 32H and Jurkat 32H-AS-S6 cells were left untreated or pretreated with doxycycline (Dox, 50 ng/ml) for 48 h and then exposed to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (25 ng/ml) for 12 h in the presence or absence of doxycycline. (b) HeLa-green fluorescent protein (GFP) and HeLa-GFP-AS-S6 (no. 1 and 2) cells were left untreated or exposed to 50 ng/ml TRAIL for 3 h. Cell extracts were prepared and analysed with western blotting using the indicated antibodies. (c, d) Reduction of DR4 expression in rpS6 knockdown cells. Cell extracts from HeLa rpS6 knockdown cells (GFP-AS-S6 no. 1 and sh-S6 R7 no. B1) (c) and SKHep-1 rpS6 knockdown cells (GFP-AS-S6 no. 3 and sh-S6 R7 no. 1D) (d) were analysed with western blotting using the indicated antibodies. (e, f) Reconstitution of DR4 sensitizes rpS6 knockdown cells to TRAIL. HeLa (e) and SKHep-1 (f) rpS6 knockdown cells were transiently transfected with the increasing amounts of pcDNA-DR4-HA for 12 h and then left untreated or exposed to 50 ng/ml TRAIL for 3 h. Cell death rate was evaluated by counting ethidium homodimer-1 (EtHD-1)-positive cells and bars indicate mean ± s.d. (n ¼ 3).
We then investigated the expression levels and phosphorylation status of rpS6 in several tumor cells. Western blotting showed that the relative ratio of the phospho-rpS6 to total rpS6 was lower in SKHep-1 cells than other hepatocellular carcinoma (HCC) and HeLa cells, though total amount of rpS6 is comparable to those of other cells (Figure 7a) . Especially, SKHep-1 cells express more rpS6 and less phospho-rpS6 than Chang's liver cells. Interestingly, examination of TRAIL-sensitivity showed that SKHep-1 cells were more sensitive to TRAIL-induced apoptosis (77% at 29 h) than Chang's liver cells (49% at 29 h) (Figures 7b  and c) . In addition, compared to Chang's liver cells, the reduction of rpS6 expression using shRNA effectively protected SKHep-1 cells from TRAIL-induced apoptosis (Figures 7b and c) . Thus, while the expression level of rpS6 itself is an important factor determining cells' selective sensitivity to TRAIL, these results suggest that it is an unphosphorylated form of rpS6 that shows the pro-apoptotic activity in TRAIL signaling.
Discussion
Until now, most studies have focused on the antiapoptotic activity of S6K1 by using rapamycin, an immunosuppressant that specifically inhibits mTOR and following S6K1, without showing the phosphorylationdependent function of rpS6 in apoptosis. The rpS6 is highly phosphorylated at its C terminus by kinases including S6K1 in response to various signals (Krieg et al., 1988; Franco and Rosenfeld, 1990; Pende et al., 2004) . However, the pro-apoptotic activity of rpS6 is not likely to be associated with the phosphorylated form of rpS6, though we confirmed anti-apoptotic activity of S6K1 in TRAIL signaling. Rather, the amount of unphosphorylated form of rpS6 is critical in TRAIL signaling; (1) rpS6 knockdown cells expressing the reduced amount of phospho-rpS6 were resistant to TRAIL, (2) the expression of phospho-defective rpS6 mutant sensitized tumor cells to TRAIL and (3) overexpression of phospho-mimic rpS6 mutant (SS235,6DD) did not suppress apoptosis triggered by TRAIL. Then, S6K1 may exhibit anti-apoptotic activity probably by phosphorylating other apoptosis regulator(s), such as Bad (Harada et al., 2001) , rather than rpS6, though rpS6 served as a positive marker for the activation of S6Ks.
The apoptotic activity elicited by the overexpression of rpS6 was almost same as that of GFP-fused rpS6. Thus, the protein fusion with GFP is not likely to interfere the pro-apoptotic activity of rpS6 and to impair ribosome function by the assembly of the GFP moiety. Also, the abundance of endogenous rpS6 far exceeds that of GFP-S6; the amount of exogenous rpS6 is about 20-30% or less than that of endogenous rpS6 in our expression analysis (Supplementary data Figure 2) . From gel-filtration analysis using Superose 6, we found that some portion (5%) of endogenous rpS6 protein was detected in the ribosomal-free fractions with molecular weights of 30-100 kDa (data not shown). Whether this extraribosomal rpS6 is associated with its pro-apoptotic activity or translational regulation remains to be further addressed.
Ectopic expression of rpS6 seems to marginally increase the expression level of long and short forms of FLIP in our assays, but rather sensitized tumor cells to TRAIL. Similarly, there were no significant changes in the expression levels of two FLIP variants in rpS6 knockdown cells (data not shown). These observations imply that FLIP may not be critical at least in the rpS6-mediated TRAIL signaling. To our surprise, the expression of DR4 was downregulated in rpS6 knockdown cells and reconstitution of DR4 sensitized rpS6 knockdown cells to TRAIL. Although many human tumor cells express both DR4 and DR5, the expressional regulation of DR4 seems to be different from that of DR5 (Ren et al., 2004 ; Raymond et al., 2005; Shashirekha et al., 2005) . Therefore, our current hypothesis is that rpS6 mediates TRAIL-induced apoptosis at least by regulating the expression of DR4. In addition, unphosphorylated rpS6 is not merely inactive form of the phospho-rpS6. We also found that the N terminus (residues 1-70) of rpS6 lacking the residues for phosphorylation exhibited pro-apoptotic activity and sensitized HeLa cells to TRAIL (Supplementary data Figure 5 ), suggesting that the C terminus may be important for phosphorylation-dependent negative regulation of the pro-apoptotic activity of rpS6. Taken together, although the relation between rpS6 phosphorylation and DR4 expression remains to be addressed, we propose that rpS6 mediates TRAIL-selective pro-apoptotic activity via expressional regulation of DR4 and rpS6 modification in tumor cells, providing a new insight into antitumor therapy.
Materials and methods
Cell culture and DNA transfection Jurkat 32H cells were grown in RPMI 1640 containing 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA). HeLa, HCCs and rpS6 PÀ/À MEFs cells were incubated with Dulbecco's modified Eagles medium (Invitrogen) with 10% FBS. For transient expression, cells were transfected with LipofectAMINE PLUS reagent according to the recommended methods by the manufacturer (Invitrogen). Rapamycin were purchased from Sigma (St Louis, MO, USA). HeLa and SKHep-1 cells stably expressing rpS6 anti-sense cDNA or shRNA were generated by selecting with G418.
TRAIL preparation Recombinant TRAIL preparation was described previously (Kim et al., 2003) .
Cell-based functional screening to isolate inhibitors of TRAIL-induced apoptosis The method was described previously (Kim et al., 2003) . Briefly, 2 Â 10 7 independent cDNA inserts in retroviral vector pTRA were constructed from RNAs of human lymph node, thymus, spleen and bone marrow. Retroviral packaging cells, jNX-ampho, were transfected with 10 mg of the cDNA library for 48 h and the supernatant was then collected. In toal 50 ng/ ml of TRAIL was used to induce 100% of cell death after 48 h, and the resulting TRAIL-resistant clones were separated by single cell sorter (MolFlow, Fortcollins, CO, USA). The putative clones were amplified, incubated again with TRAIL for secondary screening and analysed with FACScalibur (Becton Dickinson, Franklin Lakes, NJ, USA). Total RNA was then isolated from the putative clones using MRC Trizol reagent (Cincinnati, OH, USA) and subjected to amplification with SuperScript One-Step RT-PCR system (Invitrogen) using the library-specific primers. The resulting PCR products were then analysed with DNA sequencing.
Apoptosis assay
Flow cytometry analysis was performed with FACScalibur (Becton Dickinson) after staining cells with 50 mg/ml propidium iodide. Cell viability was determined by 0.04% Trypan blue exclusion assay or MTT assay (Kim et al., 2003) . For ethidium homodimer-1 assay, cells were stained by ethidium homodimer-1 (Molecular Probes no. 37149A; Eugene, OR, USA) and death rates were determined by ethidium homodimer-1-positive cells under a fluorescence microscope (Zeiss, Jena, Germany). For morphology-based death assay, GFPpositive cells showing condensed and fragmented nuclei after staining with Hoechst 33258 were counted under a fluorescence microscope.
DNA construction
The mammalian vector, pSUPER (Oligoengine, Seattle, WA, USA), was used for the expression of shRNA. The genespecific inserts specify a 19-nucleotide sequence corresponding to nucleotides 576-594 downstream of the transcription start site of rpS6 (R7), which are separated by a 9-nucleotide noncomplementary spacer (TCTCTTGAA) from the reverse complement of the same 19-nucleotide sequence. The complimentary oligonucleotides were hybridized and ligated into BglII and HindIII sites of pSUPER. The rpS6 cDNA (GFP-S6) and its anti-sense (GFP-AS-S6) were inserted into GFP-N1 (Clontech, Mountain View, CA, USA). Full-length cDNAs of rpS6, rpS2, rpS3, rpS20 and DR4 were subcloned into pcDNA3. rpS6 mutants S6-S235A, S6-S236A, S6-SS235,6AA and S6-SS235,6DD were generated by Quickchange SiteDirected Mutagenesis kit (Stratagene, La Jolla, CA, USA) using synthetic oligonucleotides containing mutations in the corresponding positions. All mutants were verified by DNA sequencing analysis.
Western blot analysis
Total 30-50 mg of cell extracts were used for western blotting (Kim et al., 2003) . The following antibodies were used: antirpS6 (Cell Signaling no. 2212, Beverly, MA, USA), antiphospho-rpS6 (Cell Signaling no. 2211), anti-DR4 (Pharmingen no. 556544; San Diego, CA, USA), anti-DR5 (ProSci no. 2019, San Diego, CA, USA), anti-FADD (Pharmingen no. 610400), anti-caspase-3 (Cell Signaling no. 9662), anti-caspase-8 (Kim et al., 2000) , anti-phospho-AKT (Cell Signaling no. 9271), anti-AKT (Cell Signaling no. 9272), anti-phospho-S6K1 for threonine 389 (Cell Signaling no. 9205), anti-phospho-4EBP-1 for threonine 37/46 (Cell Signaling no. 9459) and anti-a-tubulin antibodies (Sigma).
Statistical analysis
Results comparing three or more samples were analysed using analysis of variance (ANOVA) and Bonferroni tests, or two samples were analysed by t-test. Only P-values o0.05 were considered significant. Statistical analysis was performed using SigmaPlot program.
Abbreviations CHX, cycloheximide; DR4/DR5, death receptor 4/5; mTOR, mammalian target of rapamycin; rpS6, ribosomal protein S6; rpS6 PÀ/À MEFs, unphosphorylatable rpS6 knock-in mouse embryonic fibroblast; shRNA, short hairpin RNA; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
